 CureVac BV NASDAQ: CVAC has announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GlaxoSmithKline Plc NYSE: GSK, in the journal Nature. Related Link: CureVac-GSKs Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study. 